ACD 856
Alternative Names: ACD-856Latest Information Update: 28 Apr 2025
At a glance
- Originator AlzeCure
- Class Antidementias; Antidepressants; Neuroprotectants; Sleep disorder therapies; Small molecules; Triazines
- Mechanism of Action TrkA receptor agonists; TrkB receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cognition disorders
Highest Development Phases
- Preclinical Depressive disorders
- No development reported Alzheimer's disease; Sleep disorders; Traumatic brain injuries
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for phase-I development in Alzheimer's-disease(In volunteers) in Sweden (PO)
- 28 Apr 2025 No recent reports of development identified for preclinical development in Sleep-disorders in Sweden
- 28 Apr 2025 No recent reports of development identified for preclinical development in Traumatic-brain-injuries in Sweden